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Abstract
A step toward the molecular classification of prostate cancer was the discovery of recurrent erythroblast transformation–
specific rearrangements, most commonly fusing the androgen-regulated TMPRSS2 promoter to ERG. The TMPRSS2-ERG
fusion is observed in around 90% of tumors that overexpress the oncogene ERG. The goal of the current study was to com-
plete the characterization of these ERG-overexpressing prostate cancers. Using fluorescence in situ hybridization and reverse
transcription–polymerase chain reaction assays, we screened 101 prostate cancers, identifying 34 cases (34%) with the
TMPRSS2-ERG fusion. Seven cases demonstrated ERG rearrangement by fluorescence in situ hybridization without the pres-
ence of TMPRSS2-ERG fusion messenger RNA transcripts. Screening for known 5′ partners, we determined that three cases
harbored the SLC45A3-ERG fusion. To discover novel 5′ partners in these ERG-overexpressing and ERG-rearranged cases, we
used paired-end RNA sequencing. We first confirmed the utility of this approach by identifying the TMPRSS2-ERG fusion in a
known positive prostate cancer case and then discovered a novel fusion involving the androgen-inducible tumor suppressor,
NDRG1 (N-myc downstream regulated gene 1), and ERG in two cases. Unlike TMPRSS2-ERG and SCL45A3-ERG fusions, the
NDRG1-ERG fusion is predicted to encode a chimeric protein. Like TMPRSS2, SCL45A3 and NDRG1 are inducible not only by
androgen but also by estrogen. This study demonstrates that most ERG-overexpressing prostate cancers harbor hormonally
regulated TMPRSS2-ERG, SLC45A3-ERG, or NDRG1-ERG fusions. Broader implications of this study support the use of RNA
sequencing to discover novel cancer translocations.
Neoplasia (2009) 11, 804–811
Abbreviations: RT-PCR, reverse transcription–polymerase chain reaction; FISH, fluorescence in situ hybridization; RNA-seq, RNA sequencing; (b/a), break-apart
Address all correspondence to: Mark A. Rubin, MD, Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Ave, Room C 410-A, New York, NY 10021.
E-mail: rubinma@med.cornell.edu
1This work was supported by National Institutes of Health (NIH)/National Cancer Institute grant R01 CA125612 (M.A.R. and F.D.), Heinrich Warner Foundation (D.P.),
Department of Defense grant PC61474 (S.P.), and NIH/National Human Genome Research Institute (NHGRI) grant R44HG004237 (M.S.C.). The authors thank the
support of the “Yale University Biomedical High Performance Computing Center” and NIH grant no. RR19895 that funded the computer cluster instrumentation.
2This article refers to supplementary materials, which are designated by Tables W1 to W4 and Figures W1 to W5 and are available online at www.neoplasia.com.
3These authors contributed equally to this work.
Received 3 April 2009; Revised 16 May 2009; Accepted 20 May 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.09572
www.neoplasia.com
Volume 11 Number 8 August 2009 pp. 804–811 804
Introduction
Most prostate cancers detected through prostate-specific antigen (PSA)
screening harbor an acquired recurrent chromosomal rearrangement
[1]. The promoter region of the androgen-regulated transmembrane
protease, serine 2 (TMPRSS2) gene, is most often fused to the coding
region of members of the erythroblast transformation–specific (ETS)
family of transcription factors, most commonly v-ets erythroblastosis
virus E26 oncogene homolog (avian) (ERG ). Other, less common,
fusion events occur involving ETS family members (ETV1, ETV4,
and ETV5) fused to TMPRSS2 or other 5′ partners that differ in their
prostate specificity and response to androgen (SLC45A3, HERV-K,
C15orf21, HNRPA2B1, FLJ35294, DDX5, CANT1, and KLK2, re-
viewed by Kumar-Sinha et al. [2] and more recently, ACSL3 [3]). More-
over, variations in the structure of the gene fusions in prostate cancer
yielding different fusion transcript isoforms have been reported [4].
Emerging data suggest that ETS-rearranged prostate cancer, similar
to other translocation tumors, represent a distinct molecular subclass of
prostate cancer based on studies demonstrating characteristic morpho-
logic features [5], natural history [6,7], and specific genomic [8] and
expression profiles [9]. Herein, we report a comprehensive characteri-
zation for ERG gene rearrangements in prostate cancer including the
identification of a novel hormone-regulated 5′ fusion partner using
paired-end RNA sequencing (RNA-seq).
Materials and Methods
Patient Population
The study is composed of 101 men with localized and locally ad-
vanced prostate cancer who underwent radical prostatectomy as a
monotherapy. All prostate cancer cases were collected as part of institu-
tional review board–approved research protocols.
Sample Processing for RNA Analyses
Hematoxylin and eosin slides were prepared from formalin-fixed
paraffin-embedded material and evaluated for cancer extent and tumor
grade (Gleason score). Hematoxylin and eosin slides were prepared
from the corresponding frozen tissue block and evaluated for the ex-
tent of cancer involvement. To ensure for a high concentration of can-
cer cells and minimized benign tissue, tumor isolation was performed
by first selecting for high-density cancer foci (<10% stromal and other
nontumor tissue contamination) and then taking 1.5-mm biopsy cores
from the frozen tissue block for RNA extraction. Sections for fluo-
rescence in situ hybridization (FISH) evaluation were taken from the
frozen tissue block used for molecular analysis. The cancer foci se-
lected for RNA extraction were well characterized by FISH to evaluate
the ERG rearrangement status throughout the entire focus. We took
special care to extract the RNA from a single cancer focus to exclude
the problem of heterogeneity when looking for putative fusion tran-
scripts. RNA was isolated from frozen tissue using TRIzol LS reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions. After DNase treatment (Invitrogen), RNA concentration was
measured using a NanoDrop 8000 spectrophotometer (Thermo Scien-
tific, Wilmington, DE). Quality was assessed using the Bioanalyzer
2100 (Agilent Technologies, Inc, Santa Clara, CA). The qualitative
detection of fusion transcripts in the cases was performed using con-
ventional reverse transcription–polymerase chain reaction (RT-PCR),
agarose gel fractionation/purification, and subsequent complementary
DNA (cDNA) sequencing. For this, amplified DNA fragments cor-
responding to the expected sizes of fusion transcripts were gel-extracted
using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA) and
sequenced at the Life Sciences Core Laboratories Center’s DNA se-
quencing facility of Cornell University (Ithaca, NY). Quantitative
ERG and TMPRSS2-ERG RT-PCR was performed using QuantiTect
SYBRGreen PCRKit (Qiagen). Each sample was run in duplicate. The
amount of each target gene relative to a control gene was determined
using the comparative C t method (ABI Bulletin 2; Applied Biosys-
tems, Foster City, CA). C t values for ERG were first normalized using
the average C t values obtained for SART3 and TCFL1/VPS72 and
then calibrated using normalized C t values obtained from benign pros-
tate. Protocols and primers are shown in Table W2.
Assessment of ERG, TMPRSS2, SLC45A3, and NDRG1
Rearrangements Using Two-color FISH Assays
To assess for rearrangement of ERG, TMPRSS2, SLC45A3, and
NDRG1, we used break-apart (b/a) FISH assays for each gene and
fusion assays for SLC45A3-ERG or NDRG1-ERG on sections from
the corresponding frozen tissue blocks. The centromeric probes for
ERG, TMPRSS2, SLC45A3, and NDRG1 were RP11-24A11, RP11-
354C5, RP11-249H15, and RP11-185E14, respectively. The telomeric
probes for ERG, TMPRSS2, SLC45A3, and NDRG1 were RP11-
372O17, RP11-891L10, RP11-131E5, and RP11-1145H17, respec-
tively. We used probes RP11-131E5 (SLC45A3), RP11-1145H17
(NDRG1), and RP11-24A11 (ERG) for the SLC45A3-ERG and
NDRG1-ERG fusion assays. Correct chromosomal probe localization
was confirmed on normal lymphocyte metaphase preparations (see
Figure W4 for metaphase results for bacterial artificial chromosomes
(BACs) targeting NDRG1 locus). For each sample, a minimum of
100 nuclei were analyzed.
RNA-seq and Data Analysis
We used the Illumina Genome Analyzer II for paired-end RNA-
sequencing. This provided a pair of approximately 30 to 36 base reads,
from each end of a transcript fragment of relatively well-defined length
(approximately 330 nucleotides). The paired reads were aligned inde-
pendently to the human genome (hg18 assembly in the UCSC genome
browser1: Homo_Sapiens March 2006) using “eland,” a short-read
alignment tool included in the Genome Analyzer software suite. For
each read, eland provides the coordinate(s) of the alignment to the
reference genome, allowing for up to two mismatches in the sequence.
We kept only the reads that are mapped uniquely to the genome,
although they might have up to two mismatches. To search for novel
translocations involving ERG, two strategies were applied. First, we
selected for mapped paired reads that are more than 2 Mb apart. This
allows us to identify translocations similar to TMPRSS2-ERG messen-
ger RNA (mRNA). Indeed, the two genes are approximately 3 Mb
apart. Second, paired reads mapping to different chromosomes were
also selected as potential candidates. Because we focused on novel
ERG partners, we selected for paired reads where one of the reads lies
within ERG. This allowed us to identify several candidate fusion tran-
scripts spanning all chromosomes. We finally selected the chromosome
with the highest number of reads and checked if those reads lie within
a gene. This approach yielded numerous leads, which, because of the
low number of copies (from one to three reads), were considered back-
ground. We also identified numerous examples of putative fusions
1http://genome.ucsc.edu.
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that ambiguously mapped to multiple sites along the reference genome
probably because of the small size of the paired reads (between 30 and
36 bp). Sequences for NDRG1-ERG v1 and v2 have been submitted to
GenBank (Accession Nos. FJ627786 and FJ627787, respectively).
Hormone Treatment of LNCaP Cells
The prostate cancer cell line LNCaP was obtained from ATCC
(Manassas, VA; catalog No. CRL-1740) and maintained according
to the supplier’s instructions. For hormonal treatment, cells were
plated (500,000 cells/10 cm2) in the presence of complete growth
medium supplemented with 1% penicillin/streptomycin. Cells were
starved for 48 hours in charcoal-stripped medium (RPMI-1640 1×,
5% charcoal-stripped FBS, 1% penicillin/streptomycin) and then
treated with R1881 (1 nM), 17β-estradiol (10 nM), diarylpropio-
nitrile (DPN, 10 nM) or ethanol vehicle for 3, 12, and 24 hours.
RNA was extracted using the TRIzol reagent (Invitrogen), subjected
to DNase treatment (DNA-free Kit; Applied Biosystems) according
to the manufacturer’s instructions. To test for the specificity of andro-
gen stimulation, cells were treated with 10 μM flutamide for 2 hours
and then treated with R1881 as described previously. TaqMan assays
(Table W3) were used to quantify relative levels of SLC45A3, NDRG1,
PSA (KLK3), and IGF1R.
Results
TMPRSS2-ERG and SLC45A3-ERG Account for 84% of
ERG Overexpression in Prostate Cancer
We screened prostate cancer cases from 101 men with localized and
locally advanced prostate cancer who underwent radical prostatectomy
for ERG gene rearrangement using a FISH b/a assay. In total, 44 cases
were positive for ERG rearrangement. Given the heterogeneity of
TMPRSS2-ERG mRNA expression level [4] in prostate cancer, we
screened for TMPRSS2-ERG mRNA variant expression using con-
ventional RT-PCR and cDNA sequencing. Of the 44, 34 (77%) ex-
pressed seven different variants of TMPRSS2-ERG mRNA described
by Wang et al. [4]. To determine the level of ERG mRNA over-
expression, we performed quantitative PCR using cDNA from 29 cases
(19 that were TMPRSS2-ERG mRNA-positive and 10 TMPRSS2-
ERG mRNA-negative), 15 cases that did not show ERG rearrangement
and 6 benign prostate tissue samples (Figure 1A). ERG mRNA was
overexpressed up to 75 times (median, 27) in ERG-rearranged cases
compared with baseline levels in benign prostate tissue and cases nega-
tive for both ERG rearrangement and TMPRSS2-ERG mRNA. Con-
trary to findings by Wang et al., TMPRSS2-ERG mRNA isoform
expression was not associated with ERG overexpression or with prostate
cancer progression (Gleason score, pathologic stage, or surgical margin
status; Table W1).
TMPRSS2-ERG mRNA was absent in 10 (23% of 44) ERG-
rearranged cases, of which 7 expressed high ERG mRNA levels (5-
38 times). To confirm the absence of TMPRSS2 rearrangement in
these cases, we performed FISH using a TMPRSS2 b/a assay. We
observed TMPRSS2 rearrangement in 2 of 10 cases (60T and 51T)
suggesting a novel TMPRSS2-ERG fusion that was not detected
using standard RT-PCR approaches. Targeting the exon boundary
of exons 1 and 2 in TMPRSS2, we detected a TMPRSS2-ERG
fusion transcript in sample 60T that lacks the 5′ end of TMPRSS2
exon 1. This isoform (isoform VII) has been previously reported
[4]. To screen for other possible fusion events with ERG, we per-
formed RT-PCR analysis targeting known ETS family fusion partners
(SLC45A3, HERV-K, C15ORF21, HNRPA2B1, DDX5, CANT1,
KLK2, and ACSL3). This screening revealed that exon 4 of ERG was
fused to exon 1 of SLC45A3 in three ERG mRNA-overexpressed cases
(34T, 150B_M, and 145C_M; Figure 1B). This is consistent with the
recent report from Han et al. [10]. The predicted open reading frame is
identical to what is encoded by the most commonTMPRSS2 (exon 1)–
ERG (exon 4) mRNA transcript. We confirmed this fusion in situ using
an SLC45A3 b/a assay and SLC45A3-ERG fusion assay (Figure 1C).
Massively Parallel RNA-seq Discovers NDRG1-ERG Fusion
Prostate Cancer
Having characterized all but two ERG-overexpressing/ERG-rearranged
cases (509B and 99T), we used paired-end RNA-seq to identify po-
tential 5′ partners (Table W4). Initially, we explored for fusion tran-
scripts by looking for paired reads where each pair mapped to regions
that were either greater than 2 Mb and less than 5 Mb, greater than
5 Mb and less than 10 Mb, or greater than 10 Mb apart from each
other on chromosome 21. We also explored for fusion transcripts be-
tween ERG and reads that mapped to different chromosomes. Spurious
fusion candidates occur for a few reasons. The main reason is the mis-
alignment of the short-read sequences against the reference genome.
Another source of potential error is the creation of random chimeric
fragments during sample preparation. Therefore, to reduce these false
fusion reads, we required that the fusion candidate have several sup-
porting paired reads. First, in prostate cancer cases known to harbor
the TMPRSS2-ERG fusion (e.g., case 1701A), we detected numerous
TMPRSS2-ERG transcripts as the only fusion transcript arising within
chromosome 21 as demonstrated in Figure 2. Second, SLC45A3-ELK4
transcripts were also detected in case 1701A as we have previously ob-
served [11]. There were a few potential ERG fusion transcripts with
paired reads to different chromosomes with less than four supporting
reads suggesting that they are artificial. Finally, in one case (99T) with
ERG overexpression but no SLC45A3 or TMPRSS2 rearrangement as
determined by RT-PCR and FISH, RNA-seq demonstrated 17 copies
of a fusion transcript that mapped paired reads to ERG and to exons
of NDRG1 (Figure 3A). This was confirmed by conventional RT-PCR
(Figure 3B). Screening other TMPRSS2-ERG, SLC45A3-ERG
mRNA–negative cases revealed another, slightly different, NDRG1-
ERG transcript variant (variant 2) in 509B. We confirmed this trans-
location at the genome level using NDRG1 b/a and NDRG1-ERG
fusion FISH assays (Figure 3, C and D).
TMPRSS2-, SLC45A3-, and NDRG1-ERG Are Regulated
by Androgen and Estrogen
ERG mRNA expression in cases positive for SLC45A3-ERG or
NDRG1-ERG is similar in magnitude to those measured for TMPRSS2-
ERG-positive cases. TMPRSS2 [12], SLC45A3 [13], andNDRG1 [14–
16] are all known androgen-induced genes. This was confirmed by
treating LNCaP with a synthetic androgen (R1881, 1 nM; Figure 4,
A and B). Androgen regulation of NDRG1 is supported by the ob-
servation of an AR binding site ∼30 kb upstream of the start site
(chr8:134407748-134408779) in LNCaP cells (Figure W3). The in-
duction of gene expression was abrogated in the presence of flutamide.
If we consider KLK3 (PSA) mRNA a surrogate read-out of andro-
gen signaling, we might expect to find similar profiles between PSA
and ERG mRNA levels in TMPRSS2-ERG, SLC45A3-ERG, or
NDRG1-ERG mRNA-positive prostate cancer cases. PSA mRNA lev-
els, however, did not mimic the pattern of ERG mRNA levels in
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TMPRSS2-ERG, SLC45A3-ERG, or NDRG1-ERG mRNA-positive
cases, suggesting an additional mechanism for the regulation of the
fusion transcripts (Figure W2).
We have previously shown that TMPRSS2-ERG is regulated by
estrogen [9]. SLC45A3 may also be similarly regulated by estrogen
because the chromosome immunoprecipitation data generated by
Brown et al. indicate the presence of an estrogen receptor (ER) binding
site within the SLC45A3 gene (referenced in [11]). In addition, their
data also show that there is an ER binding site in the first intron of
NDRG1 (chr8:134373799-134375086) and another ER binding site
(chr8:134441414-134442401) ∼60 kb upstream of the start site
(Figure W3). Interestingly, similar data show that FoxA1, a known
ER cofactor, binding sites overlap with the ER binding sites. To test
if estrogen regulates gene expression, we measured the levels of SLC45A3
or NDRG1 mRNA in LNCaP cells at different time points as a func-
tion of estrogen treatment. We observed induction of SLC45A3 mRNA
3 hours (Figure 4C) and that of NDRG1 mRNA 12 hours (Figure 4D)
after 17β-estradiol treatment but not with the ERβ receptor agonist DPN
similar to IGF1R mRNA, a known estrogen-induced gene in LNCaP
cells [17] (Figure W1). These data suggest that, like TMPRSS2-ERG,
SLC45A3-ERG and NDRG1-ERG fusion genes might also be estrogen-
regulated through ERα. This would provide another mechanism for
Figure 1. ERG mRNA expression in prostate cancer and benign tissue. (A) Quantitative RT-PCR of ERG expression in 29 ERG rearranged
(including 19 TMPRSS2-ERG mRNA-positive (orange) and unknown mechanism–ERG (?–ERG, green)), 15 ERG nonrearranged (blue), and
6 benign prostate tissue samples (gray). (B) Exon composition and sequence covering the fusion junction of SLC45A3-ERG transcript.
(C) FISH images of nuclei with SLC45A3 rearrangement (upper) and SLC45A3-ERG fusion (lower) nucleus with yellow fusion signal.
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ERG overexpression when fused to SLC45A3 orNDRG1, particularly in
the case of castration-resistant prostate cancer.
Discussion
The results presented here provide further evidence of the expand-
ing variety and importance of gene fusion events in prostate cancer.
Using approaches that require a priori selection of candidate genes
(RT-PCR and FISH) and an approach that does not require a priori
gene selection (RNA-seq), we found that there are three main gene
fusions that account for ERG-overexpressing prostate cancer. Common
to all three gene fusions is a hormonally regulated promoter. The novel
NDRG1-ERG fusion is unique in that computational sequence analy-
sis of NDRG1-ERG variant 1 cDNA suggests that this fusion, as with
BCR-ABL1 fusion gene in patients with chronic myeloid leukemia,
could encode a chimeric protein containing 33 amino acids from
NDRG1 as well as the conserved protein domains of wild-type ERG
(Sterile alpha motif/Pointed domain and ETS domain). NDRG1-
ERG variant 2 mRNA is also predicted to encode a chimeric protein
including the first 21 amino acids of NDRG1 and the same conserved
domains of ERG as in the putative protein encoded by NDRG1-
ERG variant 1. A cell line model could be used to elucidate the func-
tional role of the NDRG1-ERG fusion. We screened but did not find
NDRG1-ERG mRNA in six widely used, commercially available pros-
tate cancer cell lines (LNCaP, VCaP, 22Rv1, PC-3, NCI-H660, and
DU145). We succeeded in transiently transfecting a NDRG1-ERG
variant 1 construct into HEK-293 and BPH cells and monitored the
ERG expression levels by means of quantitative RT-PCR (qRT-PCR)
and fluorescent immunostaining (Figure W5). Using a commercially
available antibody directed against ERG, we were able to show in-
creased ERG expression in the transfected cells suggesting that the
NDRG1-ERG fusion gives rise to a protein that shares downstream
sequences with wild-type ERG (data not shown). An antibody spe-
cifically targeting the fusion protein would have to be developed.
Our study differs from two recent RNA-seq studies that used either
long reads alone [18] or long and short reads [19] to identify multiple
non-ERG chimeric mRNA in a breast cancer line or prostate cell lines
and metastatic tumor samples, respectively. Here, we relied on 30 to
36 nucleotides paired-end reads from 330 nucleotides mRNA frag-
ments that have the advantage of directly identifying chimeric tran-
scripts. However, short reads cannot always be mapped uniquely to
the genome, making it impossible to unambiguously assign a location.
As the technology advances, longer paired-end RNA-seq reads will be
Figure 2. Identification of TMPRSS2-ERG fusion transcript using RNA-seq. (A) For wild-type alleles, the two paired-end reads will map to
the exons of each gene, whereas in the presence of the fusion, one read will map to exons of TMPRSS2 and the other read will map to
exons of ERG, at a much bigger distance on the genome. (B) Read pairs (<2 Mb apart) are shown as connected segments (top).
TMPRSS2 and ERG RefSeq gene annotations/locations are given (bottom). Reads of a TMPRSS2-ERG fusion–negative sample (blue)
are trimmed at the top for demonstration purposes.
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available, and the discovery of new and clinically relevant fusion tran-
scripts will become more efficient and affordable. Although this is not
the first RNA-seq paper to propose exploring for gene fusions, we were
able to exploit paired-end sequencing to discover a novel 5′ fusion
partner for ERG. This is significant because, unlike some of the other
fusions identified to date, we believe that this is recurrent and may rep-
resent up to 5% of all ERG-rearranged prostate cancers. The approach
used to make this discovery is being developed so that we can apply
this as a pipeline for other platforms and tumor types. In conclusion,
the confirmation of the TMPRSS2-ERG and discovery of theNDRG1-
ERG fusion using paired-end RNA-seq provide the first proof-of-
principle that this methodology can reliably discover novel gene fusions
in prostate cancer tissue. Alternatively, we could have used 5′RACE as
an established way of discovering gene fusions. However, this method
requires the knowledge of one partner. Although the RNA-seq analysis
approach that was developed can be directly applied to a number of
defined regions, such as ERG, we can extend to a genome-wide search
of fusions starting from paired-end reads.
The identification of NDRG1-ERG fusion prostate cancer has
potential clinical and biologic implications. NDRG1 is involved in cel-
lular differentiation, repressed by the oncogenes N-myc and c-myc
and is thus typically downregulated in cancer cells. Overexpression
of NDRG1 has also been associated with reduced metastatic potential
[20]. Therefore, hormone-induced overexpression of NDRG1-ERG
fusion leads to high levels of the functional domains of ERG but could
potentially also lead to an increased risk of metastasis due to the dis-
ruption of NDRG1. The occurrence of metastasis would have to be
correlated with differential expression of NDRG1 protein in a larger
cohort of NDRG1-ERG fusion–positive samples to be statistically re-
liable. Using only qRT-PCR techniques to indirectly monitor NDRG1
protein levels is not applicable because NDRG1 transcript levels do
not necessarily reflect NDRG1 protein levels. There are more imme-
diate clinical implications to our findings. Emerging data suggest that
ERG rearrangement–positive prostate cancer characterizes a subclass
of prostate cancers that have an aggressive natural history when left
untreated. The high levels of the unique chimeric transcripts caused
by the ETS rearrangements are only found in the disease state and
not in a benign prostate gland. Thus, the detection of fusion tran-
scripts is a logical approach to diagnose prostate cancer harboring
the ETS fusions. Several recent studies have demonstrated the ability
Figure 3. Identification of NDRG1-ERG fusion by RNA-seq. (A) The schematic shows the linear structure of NDRG1 and ERG. The gene
representation shows the “union” transcripts, that is, the exons of all isoforms are reported, and in the case of overlapping exons, the
longest one is shown. Each arc represents one instance of paired reads where one read is mapped to NDRG1 and the other to ERG. The
regions of the genes involved in the fusion transcript are highlighted and numbered. (B) Reverse transcription–PCR products obtained
using a forward primer targeting exon 1 of NDRG1 and a reverse primer targeting exon 6 of ERG (positive control: β-actin). Arrows
indicate the DNA fragments that were isolated and sequenced. Bottom panel shows sequence data from this analysis showing the
NDRG1-ERG transcript exon composition and sequence covering the fusion junction for the two variant mRNA (shown schematically)
identified in samples 99_T (top) and 509_B (bottom). (C) Schematic of the FISH NDRG1 b/a and NDRG1-ERG fusion assays. (D) NDRG1
rearrangement (upper) indicated by separated red and green signals and NDRG1-ERG fusion (lower) indicated by an overlap of the red
ERG and the green NDRG1 signal in a representative nucleus from case 99_T.
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to detect ETS fusion transcripts as well as PSA, PCA3, GOLPH2, and
SPINK1 in urine samples [21–23]. We believe that the addition of
TMPRSS2-ERG, SCL45A3-ERG, and NDRG1-ERG as part of a mul-
tiplex panel would have high specificity and improved sensitivity over
current assays.
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Supplemental Material: NDRG1-ERG Nucleic Acid
and Amino Acid Sequence
Nucleic Acid Sequence Analysis of NDRG1-ERG Fusion
Transcript Variant 1
This sequence has been deposited in GenBank (Accession
No. FJ627786).
NDRG1 ex 1-3 – ERG ex 4-12
aacaaacctcgcctggctcccagctggtgctgaagctcgtcagttcaccatccgccctcggcttccgcggggcgctgggccgc-
cagcctcggcaccgtcctttcctttctccctcgcgttaggcaggtgacagcagggacatgtctcgggagatgcaggatgta-
gacctcgctgaggtgaagcctttggtggagaaaggggagaccatcaccggcctcctgcaagagtttgatgtccaggaagcct-
tatcagttgtgagtgaggaccagtcgttgtttgagtgtgcctacggaacgcca-
cacctggctaagacagagatgaccgcgtcctcctccagcgactatggacagacttc-
caagatgagcccacgcgtccctcagcaggattggctgtctcaacccccagccagggt-
caccatcaaaatggaatgtaaccctagccaggtgaatggctcaaggaactctcctgat-
gaatgcagtgtggccaaaggcgggaagatggtgggcagcccagacaccgttgggat-
gaactacggcagctacatggaggagaagcacatgccacccccaaacatgaccac-
gaacgagcgcagagttatcgtgccagcagatcctacgctatggagtacagac-
catgtgcggcagtggctggagtgggcggtgaaagaatatggccttccagacgtcaa-
catcttgttattccagaacatcgatgggaaggaactgtgcaagatgaccaaggac-
gacttccagaggctcacccccagctacaacgccgacatccttctctcacatctccac-
tacctcagagagactcctcttccacatttgacttcagatgatgttgataaagcctta-
caaaactctccacggttaatgcatgctagaaacacagggggtgcagcttttattttcc-
caaatacttcagtatatcctgaagctacgcaaagaattacaactaggccagatttacca-
tatgagccccccaggagatcagcctggaccggtcacggccaccccacgccccagtc-
gaaagctgctcaaccatctccttccacagtgcccaaaactgaagaccagcgtcct-
cagttagatccttatcagattcttggaccaacaagtagccgccttgcaaatccagg-
cagtggccagatccagctttggcagttcctcctggagctcctgtcggacagctc-
caactccagctgcatcacctgggaaggcaccaacggggagttcaagatgacg-
gatcccgacgaggtggcccggcgctggggagagcggaagagcaaacccaacat-
gaactacgataagctcagccgcgccctccgttactactatgacaagaacatcatgac-
caaggtccatgggaagcgctacgcctacaagttcgacttccacgggatcgcc-
caggccctccagccccaccccccggagtcatctctgtacaagtacccctcaga-
cctcccgtacatgggctcctatcacgcccacccacagaagatgaactttgtggcg-
ccccaccctccagccctccccgtgacatcttccagtttttttgctgccccaaaccca-
tactggaattcaccaactgggggtatataccccaacactaggctccccaccagcca-
tatgccttctcatctgggcacttactactaaagacctggcggaggcttttcccat-
cagcgtgcattcaccagcccatcgccacaaactctatcggagaacatgaatcaaaa-
gtgcctcaagaggaatgaaaaaagctttactggggctggggaaggaagccggg-
gaagagatccaaagactcttgggagggagttactgaagtcttactacagaaatgag-
gaggatgctaaaaatgtcacgaatatggacatatcatctgtggactgaccttgtaaaa-
gacagtgtatgtagaagcatgaagtcttaaggacaaagtgccaaagaaagtggtct-
taagaaatgtataaactttagagtagagtttggaatcccactaatgcaaactgggat-
gaaactaaagcaatagaaacaacacagttttgacctaacataccgtttataatgc-
cattttaaggaaaactacctgtatttaaaaatagaaacatatcaaaaacaagagaaaa-
gacacgagagagactgtggcccatcaacagacgttgatatgcaactgcatgg-
catgtgctgttttggttgaaatcaaatacattccgtttgatggacagctgtcagctttct-
caaactgtgaagatgacccaaagtttccaactcctttacagtattaccgggactat-
gaactaaaaggtgggactgaggatgtgtatagagtgagcgtgtgattgtagaca-
gaggggtgaagaaggaggaggaagaggcagagaaggaggagaccaggctgg-
gaaagaaacttctcaagcaatgaagactggactcaggacatttggggactgtgta-
caatgagttatggagactcgagggttcatgcagtcagtgttataccaaacccagtgt-
taggagaaaggacacagcgtaatggagaaagggaagtagtagaattcagaaa-
caaaaatgcgcatctctttctttgtttgtcaaatgaaaattttaactggaattgtctga-
tatttaagagaaacattcaggacctcatcattatgtgggggctttgttctccacagggt-
caggtaagagatggccttcttggctgccacaatcagaaatcacgcaggcattttggg-
taggcggcctccagttttcctttgagtcgcgaacgctgtgcgtttgtcagaatgaag-
tatacaagtcaatgtttttccccctttttatataataattatataacttatgcatttata-
cactacgagttgatctcggccagccaaagacacacgacaaaagagacaatcgata-
taatgtggccttgaattttaactctgtatgcttaatgtttacaatatgaagttattagttct-
tagaatgcagaatgtatgtaataaaataagcttggcctagcatggcaaatcagattta-
tacaggagtctgcatttgcactttttttagtgactaaagttgcttaatgaaaacat-
gtgctgaatgttgtggattttgtgttataatttactttgtccaggaacttgtgcaaggga-
gagccaaggaaataggatgtttggcaccc
Protein Sequence Analysis of NDRG1-ERG Fusion Transcript
Variant 1
The longest chimeric sequence is analyzed by InterProScan to search
for protein domains.
Variant 1: NDRG1 ex 1-3 – ERG ex 4-12
MSREMQDVDLAEVKPLVEKGETITGLLQEFDVQEALSVV-
SEDQSLFECAYGTPHLAKTEMTASSSSDYGQTSKM-
SPRVPQQDWLSQPPARVTIKMECNPSQVNGSRNSPDECS-
VAKGGKMVGSPDTVGMNYGSYMEEKHMPPPNMTTNERR-
VIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQ-
NIDGKELCKMTKDDFQRLTPSYNADILLSHLHYLRET-
PLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPNTSVY-
PEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQ-
PSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQ-
LWQFLLELLSDSSNSSCITWEGTNGEFKMTDPDEVARRW-
GERKSKPNMNYDKLSRALRYYYDKNIMTKVHGK-
RYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSY-
HAHPQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTG-
GIYPNTRLPTSHMPSHLGTYY
Nucleic Acid Sequence Analysis of NDRG1-ERG Fusion
Transcript Variant 2
This sequence has been deposited in GenBank (Accession
No. FJ627787).
Variant 2: NDRG1 ex 1-2 – ERG ex 4-12
aacaaacctcgcctggctcccagctggtgctgaagctcgtcagttcaccatccgccctcggcttccgcggggcgctgggccg-
ccagcctcggcaccgtcctttcctttctccctcgcgttaggcaggtgacagcagggacatgtctcgggagatgcaggatgtagacc-
tcgctgaggtgaagcctttggtggagaaaggggaggaagccttatcagttgtgagtgaggaccagtcg-
ttgtttgagtgtgcctacggaacgccacacctggctaagacagagatgaccgcgtcc-
tcctccagcgactatggacagacttccaagatgagcccacgcgtccctcagcagg-
attggctgtctcaacccccagccagggtcaccatcaaaatggaatgtaaccctagc-
caggtgaatggctcaaggaactctcctgatgaatgcagtgtggccaaaggcgggaa-
gatggtgggcagcccagacaccgttgggatgaactacggcagctacatggagga-
gaagcacatgccacccccaaacatgaccacgaacgagcgcagagttatcgtgccag-
cagatcctacgctatggagtacagaccatgtgcggcagtggctggagtgggcggt-
gaaagaatatggccttccagacgtcaacatcttgttattccagaacatcgatgggaag-
gaactgtgcaagatgaccaaggacgacttccagaggctcacccccagctacaacgc-
cgacatccttctctcacatctccactacctcagagagactcctcttccacatttgactt-
cagatgatgttgataaagccttacaaaactctccacggttaatgcatgctagaaacac-
agggggtgcagcttttattttcccaaatacttcagtatatcctgaagctacgcaaagaa-
ttacaactaggccagatttaccatatgagccccccaggagatcagcctggaccggt-
cacggccaccccacgccccagtcgaaagctgctcaaccatctccttccacagtgcc-
caaaactgaagaccagcgtcctcagttagatccttatcagattcttggaccaacaag-
tagccgccttgcaaatccaggcagtggccagatccagctttggcagttcctcctgga-
gctcctgtcggacagctccaactccagctgcatcacctgggaaggcaccaacgg-
ggagttcaagatgacggatcccgacgaggtggcccgg-cgctggggagagcggaa-
gagcaaacccaacatgaactacgataagctcagccgcgccctccgttactactatga-
caagaacatcatgaccaaggtccatgggaagcgctacgcctacaagttcgacttc-
cacgggatcgcccaggccctccagccccaccccccggagtcatctctgtacaagta-
cccctcagacctcccgtacatgggctcctatcacgcccacccacagaagatgaactt-
tgtggcgccccaccctccagccctccccgtgacatcttccagtttttttgctgccccaa-
acccatactggaattcaccaactgggggtatataccccaacactaggctccccac-
cagccatatgccttctcatctgggcacttactactaaagacctggcggaggcttttcc-
catcagcgtgcattcaccagcccatcgccacaaactctatcggagaacatgaat-
caaaagtgcctcaagaggaatgaaaaaagctttactggggctggggaaggaagcc-
ggggaagagatccaaagactcttgggagggagttactgaagtcttactacagaaat-
gaggaggatgctaaaaatgtcacgaatatggacatatcatctgtggactgaccttg-
taaaagacagtgtatgtagaagcatgaagtcttaaggacaaagtgccaaagaaag-
tggtcttaagaaatgtataaactttagagtagagtttggaatcccactaatgcaaact-
gggatgaaactaaagcaatagaaacaacacagttttgacctaacataccgtttata-
atgccattttaaggaaaactacctgtatttaaaaatagaaacatatcaaaaacaaga-
gaaaagacacgagagagactgtggcccatcaacagacgttgatatgcaactgca-
tggcatgtgctgttttggttgaaatcaaatacattccgtttgatggacagctgtcag-
ctttctcaaactgtgaagatgacccaaagtttccaactcctttacagtattaccgggac-
tatgaactaaaaggtgggactgaggatgtgtatagagtgagcgtgtgattgtagaca-
gaggggtgaagaaggaggaggaagaggcagagaaggaggagaccaggctgg-
gaaagaaacttctcaagcaatgaagactggactcaggacatttggggactgtgta-
caatgagttatggagactcgagggttcatgcagtcagtgttataccaaacccagtgt-
taggagaaaggacacagcgtaatggagaaagggaagtagtagaattcagaaa-
caaaaatgcgcatctctttctttgtttgtcaaatgaaaattttaactggaattgtctgata-
tttaagagaaacattcaggacctcatcattatgtgggggctttgttctccacagggt-
caggtaagagatggccttcttggctgccacaatcagaaatcacgcaggcattttggg-
taggcggcctccagttttcctttgagtcgcgaacgctgtgcgtttgtcagaatgaag-
tatacaagtcaatgtttttccccctttttatataataattatataacttatgcatttataca-
ctacgagttgatctcggccagccaaagacacacgacaaaagagacaatcgata-
taatgtggccttgaattttaactctgtatgcttaatgtttacaatatgaagttattagttct-
tagaatgcagaatgtatgtaataaaataagcttggcctagcatggcaaatcagattta-
tacaggagtctgcatttgcactttttttagtgactaaagttgcttaatgaaaacat-
gtgctgaatgttgtggattttgtgttataatttactttgtccaggaacttgtgcaaggga-
gagccaaggaaataggatgtttggcaccc
Protein Sequence Analysis of NDRG1-ERG Fusion Transcript
Variant 2
The longest chimeric sequence is analyzed by InterProScan to search
for protein domains.
Variant 2: NDRG1 ex 1-2 – ERG ex 4-12
MSREMQDVDLAEVKPLVEKGEEALSVVSEDQSLFE-
CAYGTPHLAKTEMTASSSSDYGQTSKMSPRVPQQDWLSQP-
PARVTIKMECNPSQVNGSRNSPDECSVAKGGKMVG-
SPDTVGMNYGSYMEEKHMPPPNMTTNERRVIVPAD-
PTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDG-
KELCKMTKDDFQRLTP SYNAD I LL SHLHYLRET-
PLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPNTSVY-
PEATQR ITTRPDLPYEP PRR SAWTGHGHPTPQS -
KAAQPSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSG-
QIQLWQFLLELLSDSSNSSCITWEGTNGEFKMTDPDE-
VARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHGK-
RYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSY-
HAHPQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTG-
GIYPNTRLPTSHMPSHLGTYY
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Table W1. ERG Rearrangement and Overexpression in the Context of TMPRSS2-ERG mRNA Variants Defined Using Conventional RT-PCR and cDNA Sequencing and in the Context of the
Indicated Clinical Information.
Sample ID ERG Rearrangement TMPRSS2-ERG Isoform ERG Expression Gleason Score Stage Surgical Margin Seminal Vesicle Invasion
1701_A + III 74.04 3 + 4 IIIA − −
580_B + III, VI 66.97 3 + 4 IIC − −
1700_D + III 46.18 4 + 4 IIIA + −
28_T + III 40.40 3 + 4 IIC − −
45_T + III, VI 36.20 2 + 3 IIC + −
69_T + III, VI 32.98 4 + 3 IIIA − −
13_D + III 32.35 3 + 3 IIC − −
560_D + III, VI 30.96 4 + 3 IIIA − −
140_T + II 28.91 3 + 4 IIIA/B − +
435_D + III 28.75 3 + 4 IIIA − −
581_D + III 27.56 4 + 5 IIIB − +
1780_D + III, VI 27.10 3 + 4 IIC − −
431_D + III, VI 24.92 3 + 3 II − −
54_T + III 24.69 3 + 4 IIC + −
88_T + III 24.52 3 + 5 IIIB − +
522_D + IV 22.06 3 + 4 IIC − −
415_B + III 13.46 4 + 5 IIIA − −
67_T + II, III, VI, VIII 11.08 3 + 4 IIC − −
106_T + I, V 10.06 3 + 5 IIIB − +
60_T + − 38.40 3 + 4 IIC + −
145_C_M + − 37.54 4 + 5 IIIA − −
34_T + − 37.37 3 + 4 IIIB − +
150_B_M + − 20.06 2 + 3 IIC − −
51_T + − 15.01 3 + 4 IIIA − −
509_B + − 10.12 3 + 4 IIA − −
99_T + − 5.07 3 + 3 IIIA + −
1061_C + − 0.75 4 + 3 IIC − −
424_B + − 0.53 3 + 4 IIC − −
1043_B + − 0.50 3 + 3 IIC − −
1024_D − − 5.74 4 + 5 IIIB − +
97_T − − 2.93 2 + 3 IIC − −
127_T − − 2.72 3 + 3 IIA − −
1783_B − − 2.26 4 + 4 IIC − −
1023_C − − 1.97 3 + 3 IIC − −
113_T − − 1.77 4 + 5 IIIB + +
136_T − − 1.36 3 + 3 IIIA + −
134_B − − 1.04 3 + 2 IIB + −
1060_B − − 0.79 4 + 3 IIC − −
151_T − − 0.77 2 + 3 IIC − −
540_C − − 0.74 3 + 4 IIIA − −
1781_C − − 0.71 3 + 4 IIC + −
63_T − − 0.45 2 + 4 IIC − −
1702_C − − 0.43 3 + 4 IIIA − −
1765_A − − 0.41 3 + 4 IIA + −
1027_D NA − 1.07 NA NA NA NA
1033_B NA − 1.04 NA NA NA NA
1023_B NA − 1.04 NA NA NA NA
1024_C NA − 0.90 NA NA NA NA
1028_A NA − 0.76 NA NA NA NA
1032_D NA − 0.73 NA NA NA NA
NA indicates not applicable.
Table W2. Oligonucleotide Primers and Cycling Conditions for RT-PCR Assays.
Assay Gene Accession No. Bases Exon(s) Primer Sequence 5′ → 3′ Cycling
TMPRSS2-ERG
exon 4
TMPRSS2 NM_005656.2 −4 to 17 1 TMPRSS2-ERG_f TAGGCGCGAGCTAAGCAGGAG 94°C 2 min; 94°C 30 sec; 63°C 30 sec;
72°C 1 min 10 sec; 72°C 10 min
ERG NM_004449.3 276-252 5 Exon4_r1 GTAGGCACACTCAAACAACGACTGG 35 cycles
TMPRSS2-ERG
exon 6
TMPRSS2 NM_005656.2 −4 to 17 1 TMPRSS2-ERG_f TAGGCGCGAGCTAAGCAGGAG 94°C 2 min; 94°C 30 sec; 63°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
TMPRSS2-ERG
exon 9
TMPRSS2 NM_005656.2 −4 to 17 1 TMPRSS2-ERG_f TAGGCGCGAGCTAAGCAGGAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG 40 cycles
TMPRSS2-ERG
exon 12
TMPRSS2 NM_005656.2 −4 to 17 1 TMPRSS2-ERG_f TAGGCGCGAGCTAAGCAGGAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 1575-1549 13 ERG_Exon13_r TTAGTAGTAAGTGCCCAGATGAGAAGG 40 cycles
ERG qPCR ERG NM_004449.3 574-597 6-7 ERG_Exon 5-6_f CGCAGAGTTATCGTGCCAGCAGAT 50°C 2 min; 95°C 15 min; 94°C 1 min;
50°C 1 min; 72°C 1 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 41 cycles
SART3 NM_014706.3 635-658 2 SART3_f GCCCGCCAGAAGATGAGTGAAATC Melting curve: 70-90°C every 0.2°C
for 1 sec
SART3 NM_014706.3 889-866 4 SART3_r ACCAACAGACGAGAGAGCCCTTTC
TCFLI/VPS72 NM_005997.1 778-801 6 TCFL1/VPS72_f ATTGACTCCTCATGCTGGGACTGG
TCFLI/VPS72 NM_005997.1 948-927 6 TCFL1/VPS72_r CGGTATAGGGCTGGACGATGGG
TMPRSS2-ERG
qPCR
TMPRSS2 NM_005656.2 −4 to 17 1 TMPRSS2-ERG_f TAGGCGCGAGCTAAGCAGGAG 50°C 2 min; 95°C 15 min; 94°C 1 min;
50°C 1 min; 72°C 1 min
ERG NM_004449.3 276-252 5 Exon4_r1 GTAGGCACACTCAAACAACGACTGG 41 cycles
HMBS NM_000190.3 711-730 10 HMBS_f CCATCATCCTGGCAACAGCT Melting curve: 70-90°C every 0.2°C
for 1 sec
HMBS NM_000190.3 790-772 11 HMBS_r GCATTCCTCAGGGTGCAGG
SLC45A3-ERG SLC45A3 NM_033102.2 74-91 1 SLC45A3_f CGCTGGCTCCGGGTGACA 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
HERV-K-ERG HERV-K_22q11.23 BC020811.1 305-327 N/A HERV-K_f GTCCCAAGTACGTCCACGGTCAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
HNRPA2B1-ERG HNRPA2B1 NM_002137.2 136-155 1 HNRPA2B1_f TGCGGGAAATCGGGCTGAAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
C15ORF21-ERG C15ORF21 NM_001005266 313-336 3 C15ORF21_f CAACTAACACTGCGGCTTCCTGAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
CANT1-ERG CANT1 E1a N/A N/A N/A CANT1-E1a_f GCTGGAGAAACAAACCCTCT 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
CANT1-ERG CANT1 E1 NM_138793.2 48-65 1 CANT1-E1_f AGCCAAGCCCCGCCGATC 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
KLK2-ERG KLK2 NM_005551.3 65-77 1 KLK2_f TCTCTCCATCGCCTTGTCTGTG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
DDX5-ERG DDX5 NM_004396.2 423-443 3 DDX5_f AGAGGTCACAACTGCCCGAAG 94°C 2 min; 94°C 30 sec; 55°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
NDRG1-ERG NDRG1 NM_006096.2 30-53 1 NDRG1_ex1_f CTGAAGCTCGTCAGTTCACCATCC 94°C 2 min; 94°C 30 sec; 61°C 30 sec;
68°C 2 min; 68°C 10 min
ERG NM_004449.3 659-636 7 ERG_Exon 5-6_r CCATATTCTTTCACCGCCCACTCC 40 cycles
ERG NM_004449.3 945-928 10 ERG_Exon10_r CGACTGGGGCGTGGGGTG
ERG NM_004449.3 1575-1549 13 ERG_Exon13_r TTAGTAGTAAGTGCCCAGATGAGAAGG
ERG 5′RACE ERG mRNA 601-578 6-7 ERG_GSP1 ATCCTAGACGACCGTGCTATTGAG Reverse transcription reaction at 55°C
ERG NM_004449.3 571-552 6 ERG_GSP2 CGTTCGTGGTCATGTTTGGG 94°C 2 min; 94°C 30 sec; 60°C 1 min;
72°C 1 min; 72°C 7 min
ERG NM_004449.3 470-448 6 ERG_GSP3 GCCACACTGCATTCATCAGGAGA 35 cycles (45 cycles for GSP3-PCR)
All RT-PCR assays are listed along with the respective gene(s) investigated, GenBank, oligonucleotide primer name, its location (bases and exons), sequence (5′ to 3′), and cycling conditions.
N/A indicates not applicable.
Table W3. TaqMan Expression Assays from Applied Biosystems and Information Regarding Available
Assay ID, Reporter Dye, and Location within the Gene.
Gene Assay ID Reporter Dye Location
SLC45A3 Hs00263832_m1 FAM ex 5
TCFL1 Hs00195618_m1 FAM ex 6
IGF1R Hs99999020_m1 FAM ex 2 and 3
KLK3 Hs02576345_m1 FAM ex 1 and 2, detects all KLK3 transcript variants
NDRG1 Hs00608387_m1 FAM ex 11 and 12
We followed the manufacturer’s recommended protocol.
Table W4. Summary of the Data Obtained from Three Samples Analyzed Using RNA-Seq Showing
the Number of Reads and the Number of Mappable (Including Percentage) for Each Sample.
Sample ID No. Reads No. Mappable
Reads
% Mappable
Reads
Comments
1701_A 8,542,482 3,108,222 36.39% (T2-ERG fusion–positive)
1783_B 3,080,154 1,330,949 43.21% (T2-ERG fusion–negative)
99_T 2,844,879 1,180,781 41.51% (NDRG1-ERG fusion–positive)
Figure W1. Androgen and 17β-estradiol (E2) signaling of known target genes in LNCaP cells. PSA and IGF2RmRNA expression is induced
upon stimulation with synthetic androgen (R1881) and E2. Serum-starved LNCaP cells have been stimulated with 1 nM R1881, 1 nM R1881
in combination with 10 μM flutamide, 10 nM E2, or 10 nM DPN for 3, 12, and 24 hours. Total RNA was extracted and used for quantitative
RT-PCR using TaqMan. Samples were run in triplicate and normalized against TCFL1. Columns indicate themean fold change of induction of
three biologic replicates against vehicle (ethanol)-only treated cells for the respective time points ± SEM.
Figure W2. Expression profiling of ERG and three androgen-regulated genes. A subset of 65 of 101 samples was processed using
Illumina HumanWG-6 v2.0 bead arrays. Purple indicates three samples with SLC45A3-ERG fusion. The heat map shows the relative
expression levels of ERG, TMPRSS2, and SLC45A3. The gene expression levels in a given sample have been color coded where orange
to blue indicates high to low levels of expression. The samples have been grouped according to TMPRSS2-ERG (T2-ERG) fusion status as
determined by RT-PCR and then ordered by the level of ERG microarray feature level normalized intensity.
Figure W3. UCSC Genome Browser of the region of chromosome 8q24q22 that includes the location of NDRG1 exon and intron locations and
upstreamsequence.Shownarebindingsites forandrogen receptor (AR;MylesBrown,writtenpersonal communication, January13,2009) inLNCaP
cells and ER and FoxA1 in the MCF7 cell lines [1,2].
Figure W4. Representative image of a metaphase spread from nor-
mal human male lymphocytes displaying the correct chromosome
8q24.22 position of FISH BAC probes targeting the NDRG1 locus
used in the b/a assay.
Figure W5. Evaluation of ERG expression through qRT-PCR (A) and fluorescent immunostaining (B) of HEK-293 cells (left panels) and BPH
cells (right panels), respectively, transiently transfected with untagged NDRG1-ERG constructs. As a control, the cells were transfected with
a lacZ construct.
